文献速递胸部肿瘤

西欧真实世界队列中早期EGFR突变肺腺癌的患病率、临床与分子特征:对辅助治疗的启示

Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
PubMed 文献 · Eur J Cancer · 2022-12-19

该研究对2014年1月1日至2020年2月1日间486例肺腺癌进行无偏倚靶向二代测序,发现53例(11%)携带EGFR突变,早期(0-IIIA期)患病率为13%,晚期(IIIB-IV期)为9%;130例IB-IIIA期患者中9例(7%)符合ADAURA标准;早期病例L858R突变更多、20外显子插入更少、TP53共突变更少、从不吸烟者更多;辅助奥希替尼的需检测人数比为14.4。

要点

  • 486例肺腺癌中53例(11%)存在EGFR突变,早期(0-IIIA期)为13%,晚期(IIIB-IV期)为9%。
  • 130例IB-IIIA期患者中9例(7%)符合ADAURA研究入组标准。
  • 早期EGFR突变病例较晚期更常见L858R突变(p=0.02)、从不吸烟(p=0.04),20外显子插入(p=0.048)和TP53共突变(p=0.007)更少。

核心结论

  • 随着(新)辅助靶向治疗进入肺癌治疗领域,早期非小细胞肺癌的分子分析变得重要。
  • 在该人群中,早期肺腺癌EGFR突变检测具有可观的检出率,辅助奥希替尼的需检测人数比为14.4。
  • 早期与晚期疾病之间观察到的差异需要进一步分析,以改善预后分层和更个性化的治疗。

研究设计与样本

  • 对2014年1月1日至2020年2月1日间486例肺腺癌病例进行常规无偏倚靶向二代测序,不论TNM分期。
  • 收集临床和病理数据,包括共突变和形态学;将EGFR突变病例与KRAS突变病例进行比较以探究EGFR特异性特征。

主要发现

  • 486例肺腺癌中53例(11%)携带EGFR突变。
  • 早期(0-IIIA期)患病率为13%,晚期(IIIB-IV期)为9%。
  • 130例IB-IIIA期患者中9例(7%)符合ADAURA标准。
  • 与晚期EGFR突变病例相比,早期病例L858R突变更多(p=0.02)、20外显子插入更少(p=0.048)、TP53共突变更少(p=0.007)、从不吸烟者更多(p=0.04)。
  • KRAS突变病例较EGFR突变病例在TNM分期上分布更均匀。

局限性

  • 早期与晚期疾病之间观察到的差异需要进一步分析,以改善预后分层和更个性化的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The landmark ADAURA study recently demonstrated a significant disease-free survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung adenocarcinoma. However, data on prevalence rates and stage distribution of EGFR mutations in non-small cell lung cancer in Western populations are limited since upfront EGFR testing in early stage lung adenocarcinoma is not common practice. Here, we present a unique, real-world, unselected cohort of lung adenocarcinoma to aid in providing a rationale for routine testing of early stage lung cancers for EGFR mutations in the West-European population. MATERIAL AND METHODS: We performed routine unbiased testing of all cases, regardless of TNM stage, with targeted next-generation sequencing on 486 lung adenocarcinoma cases between 01- January 2014 and 01 February 2020. Clinical and pathological data, including co-mutations and morphology, were collected. EGFR-mutated cases were compared to KRAS-mutated cases to investigate EGFR-specific characteristics. RESULTS: In total, 53 of 486 lung adenocarcinomas (11%) harboured an EGFR mutation. In early stages (stage 0-IIIA), the prevalence was 13%, versus 9% in stage IIIB-IV. Nine out of 130 (7%) stage IB-IIIA patients fit the ADAURA criteria. Early stage cases harboured more L858R mutations (p = 0.02), fewer exon 20 insertions (p = 0.048), fewer TP53 co-mutations (p = 0.007), and were more frequently never smokers (p = 0.04) compared to late stage cases with EGFR mutations. The KRAS-mutated cases were distributed more evenly across TNM stages compared to the EGFR-mutated cases. CONCLUSION: As (neo-)adjuvant targeted therapy regimes enter the field of lung cancer treatment, molecular analysis of early stage non-small cell lung cancer becomes relevant. Testing for EGFR mutations in early stage lung adenocarcinoma holds a substantial yield in our population, as our number needed to test ratio for adjuvant osimertinib was 14.4. The observed differences between early and late stage disease warrant further analysis to work towards better prognostic stratification and more personalised treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hondelink LM, Ernst SM, Atmodimedjo P, et al. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. Eur J Cancer. 2022. PMID: 36638752. doi:10.1016/j.ejca.2022.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。